Browse by Audience
Skip to content
Papers of the Week
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Abstract
We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary cholangitis (PBC) at risk for disease progression (alkaline phosphatase [ALP] ≥1.67×upper limit of normal [ULN]) receiving or intolerant to ursodeoxycholic acid.